Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
epiliquid logo — Making cancer detection accessible for everyone

epiliquid

Making cancer detection accessible for everyone

Founded 2021 10 employees

General Information

Company Name epiliquid
Founded Year 2021
Founders / Decision Makers
Team member
Employees 10
Social

Get notified when epiliquid moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About epiliquid

Epiliquid is a biotechnology startup with the mission of "Making cancer detection accessible for everyone". The company aims to revolutionize early cancer detection by developing a liquid biopsy technology platform that is sensitive, affordable, and accessible. Epiliquid has assembled a multidisciplinary team of highly qualified professionals with extensive experience in life sciences and biotechnology. The team has developed a biomarker detection platform in blood using simple equipment, focusing on precision and mass accessibility to ensure the benefits of early cancer detection reach more people. Epiliquid leverages big data and artificial intelligence through its bioinformatic platform to identify sensitive and specific biomarkers for different types of cancer, considering their clinical utility. The company's patented technology allows for minimally invasive early cancer detection, setting a new standard in contrast to existing technologies. The liquid biopsy market is projected to reach USD 18 billion by 2032, and Epiliquid is at the forefront of this market with innovative solutions that have the potential to make a significant impact on public health globally. Epiliquid was founded in 2021 and invites investors to join its mission to detect cancer early and improve population health.

Taxonomy: Life Sciences, Healthtech, Liquid Biopsy, Medicine, Cancer, Startup, DNA, Bioinformatics, Precision Medicine, Diagnosis, Early Detection

No funding data available for epiliquid yet.

Get notified when epiliquid raises funding

epiliquid Alternatives & Competitors

epiliquid vs
Novigenix SA
Novigenix SA Switzerland

Leader in Immuno-Transcriptomic Precision Medicine solutions

Series B
26 employees
AI, Analytics
epiliquid vs
Owlstone Medical
Owlstone Medical United Kingdom

On a mission to save 100k lives and $1.5B healthcare costs

Undisclosed
208 employees
Health Care, Medical Devices
epiliquid vs
Volition
Volition United States

Revolutionizing early disease diagnosis for a brighter tomorrow

IPO
86 employees

FAQ About epiliquid

Making cancer detection accessible for everyone
epiliquid was founded in 2021.
epiliquid has approximately 10 employees.
Top alternatives and competitors to epiliquid include Novigenix SA, Owlstone Medical, Volition, Micromedic Technologies Ltd., Genetics Research. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
epiliquid and Novigenix SA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors epiliquid and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy